Inclusion Criteria:  Male or female ≥ 40 years of age and with BMI ≤ 35 kg/m2;  Uni- or bilateral femorotibial knee OA :  Responding to clinical and radiological criteria of American College of Rheumatology (ACR); Symptomatic for more than 6 months in the index knee; Radiological Kellgren & Lawrence (K&L) grade II-III in standing x-rays from less than 12 months. Mild-to-Moderate mean knee pain score at rest or at walking over the last 24 hours on the index knee evaluated on VAS (0-100) ≥ 40 at baseline; Able to follow the instructions of the study; Having signed an informed consent.  Exclusion Criteria:  Related to knee:  Recent macro-trauma of the knee responsible of the symptomatic knee left to the Investigator's discretion; Concurrent articular disease interfering with the evaluation of pain left to the Investigator's discretion; Prosthesis in the target knee;  Knee swelling requiring corticosteroids local injection.  Related to treatments:  Analgesics to manage knee pain 24 hours before inclusion visit; Corticosteroids injection in the target knee in the last 3 months; Hyaluronan injection in the target knee in the last 6 months; Arthroscopy in the last 6 months; Oral corticotherapy ≥ 5mg/day (in Prednisolone equivalent) in the last 3 months; Symptomatic slow-acting drugs for osteoarthritis (SYSADOA) or dietary supplement, i.e., curcuma extract, chondroitin, glucosamine, diacerein or avocado-soya unsaponifiables in the last 3 months; An anticipated need for any forbidden treatments during the trial;  Contraindications to the product :  severe hepatic and renal impairment congenital or acquired coagulation disorders, e.g. haemophilia severe liver and/or kidney damage hereditary galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption Hypersensitivity or allergy to the product components, and pineapple; Treatments based on strontium ranelate, bisphosphonates, selective estrogen-receptor modulator (SERM) and parathormone (PTH) in the last 12 months; Treatment based on zoledronate in the last 2 years; Treatment based on denosumab in the last 6 months;  Treatment with anticoagulants and/or anti-platelet agents  Related to associated diseases:  Any severe, uncontrolled and limiting disease left to the Investigator's discretion; Patient with widespread pain/depression (e.g. fibromyalgia); Lower or upper extremity surgery or fracture in the last 6 months; Anticipated need for any surgical or other invasive procedure during the trial including prosthesis in the target knee;  Severe alteration of mobility enabling functional evaluation.  Related to subjects  Close collaborators to the investigational team, the study coordinator (ARTIALIS) or to the Sponsor; Currently participating or having participated in another therapeutic clinical trial in the three previous months; Having made a blood donation in the past month; Under guardianship or judicial protection; Pregnancy, breastfeeding, planned conception, or premenopausal women without effective contraception (tablet, patch, ring, diaphragm, implant and intrauterine device, tubal ligation or hysterectomy); Counter-indication to an MRI examination.